Macquarie Group
EVH icon

Macquarie Group’s Evolent Health EVH Stock Holding History

Macquarie Group’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-211,418
Closed -$1.79M – 1059
2025
Q3 		$1.79M Buy
211,418
+15,438
+8% +$150K ﹤0.01% 1201
2025
Q2 		$2.21M Buy
195,980
+47,800
+32% +$439K ﹤0.01% 1192
2025
Q1 		$1.4M Sell
148,180
-3,427
-2% -$34.6K ﹤0.01% 1326
2024
Q4 		$1.71M Sell
151,607
-479,977
-76% -$8.44M ﹤0.01% 1248
2024
Q3 		$17.9M Sell
631,584
-381,048
-38% -$9.82M 0.02% 698
2024
Q2 		$19.4M Sell
1,012,632
-132,808
-12% -$3.39M 0.02% 660
2024
Q1 		$37.6M Sell
1,145,440
-23,206
-2% -$741K 0.04% 513
2023
Q4 		$38.6M Buy
1,168,646
+5,938
+0.5% +$168K 0.04% 514
2023
Q3 		$31.7M Sell
1,162,708
-366,531
-24% -$10.2M 0.04% 541
2023
Q2 		$46.3M Buy
1,529,239
+158,522
+12% +$5.13M 0.05% 454
2023
Q1 		$44.5M Buy
1,370,717
+263,885
+24% +$8.34M 0.05% 457
2022
Q4 		$31.1M Sell
1,106,832
-347,864
-24% -$9.97M 0.04% 592
2022
Q3 		$52.3M Buy
1,454,696
+270,128
+23% +$9.52M 0.06% 406
2022
Q2 		$36.4M Buy
1,184,568
+702,899
+146% +$20.5M 0.04% 562
2022
Q1 		$15.6K Buy
481,669
+209,378
+77% +$5.48M 0.01% 829
2021
Q4 		$7.53M Buy
272,291
+181,433
+200% +$5.2M 0.01% 1014
2021
Q3 		$2.82M Sell
90,858
-34,281
-27% -$823K ﹤0.01% 1275
2021
Q2 		$2.64M Hold
125,139
– – ﹤0.01% 1328
2021
Q1 		$2.53M Buy
125,139
+17,835
+17% +$339K ﹤0.01% 1111
2020
Q4 		$1.72M Sell
107,304
-8,431
-7% -$111K ﹤0.01% 1150
2020
Q3 		$1.44M Sell
115,735
-21,173
-15% -$249K ﹤0.01% 1144
2020
Q2 		$975K Buy
136,908
+3,440
+3% +$23K ﹤0.01% 1211
2020
Q1 		$725K Buy
133,468
+7,761
+6% +$69.3K ﹤0.01% 1175
2019
Q4 		$1.14M Sell
125,707
-26,386
-17% -$214K ﹤0.01% 1203
2019
Q3 		$1.09M Buy
152,093
+42,752
+39% +$307K ﹤0.01% 1189
2019
Q2 		$869K Sell
109,341
-35,923
-25% -$425K ﹤0.01% 1252
2019
Q1 		$1.83M Sell
145,264
-188,907
-57% -$2.99M ﹤0.01% 1015
2018
Q4 		$6.67M Buy
334,171
+29,833
+10% +$690K 0.01% 689
2018
Q3 		$8.64M Buy
304,338
+76,345
+33% +$1.82M 0.01% 678
2018
Q2 		$4.8M Buy
227,993
+66,371
+41% +$1.26M 0.01% 789
2018
Q1 		$2.3M Sell
161,622
-14,390
-8% -$206K ﹤0.01% 952
2017
Q4 		$2.17M Buy
176,012
+54,370
+45% +$766K ﹤0.01% 1005
2017
Q3 		$2.17M Buy
121,642
+40,917
+51% +$843K ﹤0.01% 960
2017
Q2 		$2.05M Sell
80,725
-8,287
-9% -$199K ﹤0.01% 966
2017
Q1 		$1.99M Sell
89,012
-23,999
-21% -$461K ﹤0.01% 973
2016
Q4 		$1.67M Buy
113,011
+17,718
+19% +$349K ﹤0.01% 1019
2016
Q3 		$2.35M Sell
95,293
-115,027
-55% -$2.69M ﹤0.01% 911
2016
Q2 		$4.04M Buy
+210,320
New +$2.89M ﹤0.01% 939

Other funds holding EVH

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group's EVH Position: Q4 2025 in Review

Macquarie Group sold out of Evolent Health (EVH) in Q4 2025, closing a stake of 211,418 shares — an estimated $1.79M sold.

Macquarie Group first reported a position in EVH in Q2 2016 and held it in 38 quarters. The position peaked at $52.3M in Q3 2022. 215 funds tracked by Wall St. Rank hold EVH as of Q4 2025.

  • Macquarie Group reported no remaining Evolent Health position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 211,418 Evolent Health shares in Q4 2025, an estimated $1.79M.
  • Macquarie Group first reported a position in Evolent Health in Q2 2016 and held it in 38 quarters.
  • Macquarie Group's Evolent Health position peaked at $52.3M in Q3 2022.
  • 215 funds tracked by Wall St. Rank held Evolent Health as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.